Takeda swoops in to buy stem cell partner TiGenix for $630M, putting it on the threshold of a likely approval – Endpoints News
Endpoints News |
Takeda swoops in to buy stem cell partner TiGenix for $630M, putting it on the threshold of a likely approval
Endpoints News Takeda lined up a $400 million-plus marketing pact with TiGenix on Cx601 back in 2016, drawn by an off-the-shelf stem cell therapy that is now also in a Phase III US study designed to pave the way for an OK at the FDA. TiGenix recently narrowed its … Takeda Starts the Year Bidding for a Belgian Stem Cell Therapy Biotech Takeda offers €520m for stem cell firm TiGenix Takeda to Acquire TiGenix for €520M |
